Concepedia

Multifaceted effects of soluble human CD6 in experimental cancer models

Inês Simões, Fernando Aranda, Sergi Casadó‐Llombart, María Velasco‐de Andrés, Cristina Català, Pilar Álvarez, Marta Consuegra‐Fernández, Marc Orta‐Mascaró, Ramón Merino, Jesús Merino,

Journal for ImmunoTherapy of Cancer · 2020 · 11 citations · 46 references

DOIFull text

Open access

Abstract

Evidence is provided for the disruption of CD6 receptor-ligand interactions as a feasible immunomodulatory approach in cancer.

References

46

Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection

Natalia Rubinstein, Mariano J. Alvarez, Norberto W. Zwirner et al. · Cancer Cell · 2004 · 510 citations · Full text

, , +10

Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system

Romain Cayrol, Karolina Wosik, Jennifer L. Berard et al. · Nature Immunology · 2007 · 422 citations

, , +13

Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand.

Michael A. Bowen, Dhavalkumar D. Patel, X Li et al. · The Journal of Experimental Medicine · 1995 · 383 citations · Full text

, , +19

The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6.

Matthew Peters, Samuel A. Jacobs, Marc Ehlers et al. · The Journal of Experimental Medicine · 1996 · 283 citations · Full text

, , +19

Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells

Aukje W. Zimmerman, Ben Joosten, Ruurd Torensma et al. · Blood · 2005 · 222 citations · Full text